New injection aims to control tough blood cancers in early trial
NCT ID NCT07493174
First seen Apr 02, 2026 · Last updated May 22, 2026 · Updated 7 times
Summary
This early-phase study tests a new drug called SYS6055 in about 86 adults whose B-cell blood cancers have come back or stopped responding to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors or control the disease. Participants will be closely monitored for side effects and how their cancer responds.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY B-CELL MALIGNANCIES are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.